Regeneron (REGN)
807.48
+25.44 (3.25%)
Upcoming Events
Latest Headlines
Regeneron Pharma (REGN) PT Raised to $865 at Piper Sandler
October 19, 2026 7:13 AM - StreetInsider
EU panel backs updated Libtayo dosing schedule for all cancer types
October 16, 2026 7:00 AM - StreetInsider
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
October 16, 2026 7:00 AM - StreetInsider
Form 4 REGENERON PHARMACEUTICAL For: Oct 13 Filed by: MURPHY ANDREW J
October 15, 2026 4:03 PM - SEC Filing
Form 144 REGENERON PHARMACEUTICAL Filed by: MURPHY ANDREW J
October 14, 2026 4:04 PM - SEC Filing
Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial
October 12, 2026 12:07 PM - StreetInsider
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
October 12, 2026 12:06 PM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $810 at RBC Capital
October 8, 2026 8:26 AM - StreetInsider
Raymond James maintains Outperform rating on Regeneron with $911 target
October 8, 2026 5:20 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $779 at Morgan Stanley
October 7, 2026 7:59 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $780 at Truist Securities
October 7, 2026 7:14 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $950 at JPMorgan
October 6, 2026 8:51 AM - StreetInsider
Form 8-K REGENERON PHARMACEUTICAL For: Oct 01
October 6, 2026 7:52 AM - SEC Filing
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
October 6, 2026 7:00 AM - StreetInsider
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
October 1, 2026 3:10 PM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $930 at Jefferies
October 1, 2026 12:43 PM - StreetInsider
Regeneron reports 73% response rate for ubamatamab in ovarian cancer
October 1, 2026 11:38 AM - StreetInsider
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
October 1, 2026 11:35 AM - StreetInsider
Regeneron drug shows muscle preservation in GLP-1 weight loss trial
October 1, 2026 11:30 AM - StreetInsider
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
October 1, 2026 11:30 AM - StreetInsider
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
October 1, 2026 9:45 AM - StreetInsider
Argus Upgrades Regeneron Pharma (REGN) to Buy, 'attractive entry point '
October 1, 2026 7:02 AM - StreetInsider
Regeneron and Sanofi expand alliance with $1 Bln upfront deal
October 1, 2026 1:01 AM - StreetInsider
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
October 1, 2026 1:00 AM - StreetInsider
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
October 1, 2026 1:00 AM - StreetInsider
Form 8-K REGENERON PHARMACEUTICAL For: Sep 24
September 30, 2026 4:14 PM - SEC Filing
RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
September 29, 2026 9:28 AM - StreetInsider
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
September 24, 2026 4:05 PM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $920 at HSBC
September 10, 2026 3:29 AM - StreetInsider
RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
September 1, 2026 8:56 AM - StreetInsider
Form 4 REGENERON PHARMACEUTICAL For: Aug 19 Filed by: LAROSA JOSEPH J
August 21, 2026 4:01 PM - SEC Filing
Form N-PX REGENERON PHARMACEUTICAL For: Jun 30
August 20, 2026 4:12 PM - SEC Filing
Form 4 REGENERON PHARMACEUTICAL For: Aug 18 Filed by: Fenimore Christopher R.
August 20, 2026 4:02 PM - SEC Filing
Regeneron Announces Investor Conference Presentations
August 19, 2026 4:05 PM - StreetInsider
FDA approves Regeneron's Pasatru for rare bone disorder FOP
August 19, 2026 1:58 PM - StreetInsider
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
August 19, 2026 1:58 PM - Globe NewsWire
Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
August 14, 2026 9:28 AM - StreetInsider
Form 4 REGENERON PHARMACEUTICAL For: Aug 10 Filed by: Guarini Kathryn
August 12, 2026 4:17 PM - SEC Filing
Form 4 REGENERON PHARMACEUTICAL For: Aug 10 Filed by: Zoghbi Huda Y
August 12, 2026 4:15 PM - SEC Filing
Form 144 REGENERON PHARMACEUTICAL Filed by: Zoghbi Huda Y
August 10, 2026 4:14 PM - SEC Filing
Form 144 REGENERON PHARMACEUTICAL Filed by: Guarini Kathryn
August 10, 2026 4:12 PM - SEC Filing
Form 13F-HR REGENERON PHARMACEUTICAL For: Jun 30
August 7, 2026 4:13 PM - SEC Filing
Regeneron Pharma (REGN) PT Raised to $800 at BMO Capital
July 31, 2026 8:59 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $750 at Wells Fargo
July 31, 2026 8:35 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $737 at RBC Capital
July 31, 2026 8:22 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $758 at Morgan Stanley
July 31, 2026 8:01 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $761 at Baird
July 31, 2026 7:21 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $772 at Truist Securities
July 31, 2026 7:10 AM - StreetInsider
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
July 31, 2026 7:00 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $891 at BofA Securities
July 30, 2026 1:36 PM - StreetInsider
Regeneron (REGN) Tops Q2 EPS by 371c
July 30, 2026 6:59 AM - StreetInsider
Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30
July 30, 2026 6:52 AM - SEC Filing
Form 8-K REGENERON PHARMACEUTICAL For: Jul 30
July 30, 2026 6:49 AM - SEC Filing
Tessera Therapeutics names former Merck executive as new CEO
July 23, 2026 1:00 PM - StreetInsider
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
July 23, 2026 1:00 PM - PR NewsWire
Full Article List
